Skip to content

Effect on fenugreek seed extract on Alcoholic liver disease

Efficacy of Fenugreek seed extract on improving liver functions in patients with alcoholic hepatitis: A randomized double blind placebo controlled trial. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057445
Enrollment
92
Registered
2023-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K701- Alcoholic hepatitis

Interventions

Intervention1: Fenugreek seed extract: Fenugreek seed extract 500 mg twice a day for 1 month Control Intervention1: Placebo: Placebo (Maize starch IP grade) 500 mg twice a day for 1 month

Sponsors

Jawaharlal Institute of Postgraduate Medical Education Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Alcoholic hepatitis patients of either gender aged 18–65 years with a present history of alcohol abuse as confirmed by CAGE questionnaire score =2 Patients with elevated liver enzymes levels, with AST/ALT ratio >1.5

Exclusion criteria

Exclusion criteria: Patients who are terminally ill (encephalopathy, spontaneous bacterial peritonitis, and hepatorenal syndrome) with severe alcoholic hepatitis (MDF =32), AST levels > 500 IU/L Patients with viral and drug-induced hepatitis Patients with comorbid conditions such as coronary artery disease and peripheral vascular disease Pregnant women or lactating mothers and women in reproductive age group not practicing contraceptive measures Patients who had participated in other trials in the past 3 months Patients on any other herbal medications

Design outcomes

Primary

MeasureTime frame
AST, ALT, ALP, GGT, bilirubinTimepoint: Baseline, 1 month

Secondary

MeasureTime frame
Total cholesterol, triglycerides, HDL, LDL, VLDL, hs-CRP, TNF-a, total oxidant status, total antioxidant status, adverse drug reactionsTimepoint: Baseline, 1 month

Countries

India

Contacts

Public ContactSIVARANJITH L

Jawaharlal Institute of Postgraduate Medical Education & Research

gcnx2005@gmail.com9443843946

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026